

Original Article

Open Access

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX

Mi-Jung Kim, MD^{1,2,3}, **Sae-Won Han**, MD, PhD^{1,2}, **Dae-Won Lee**, MD¹, **Yongjun Cha**, MD¹, **Kyung-Hun Lee**, MD^{1,2}, **Tae-Yong Kim**, MD^{1,2}, **Do-Youn Oh**, MD, PhD^{1,2}, **Se Hyung Kim**, MD, PhD⁴, **Seock-Ah Im**, MD, PhD^{1,2}, **Yung-Jue Bang**, MD, PhD^{1,2}, **Tae-You Kim**, MD, PhD^{1,2}

¹Department of Internal Medicine, Seoul National University Hospital, Seoul,

²Cancer Research Institute, Seoul National University College of Medicine, Seoul,

³Center for Gastric Cancer, National Cancer Center, Goyang, ⁴Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Supplementary Data

Table of Contents

Supplementary Table 1	2
-----------------------------	---

Supplementary Table 1. Primer sequences and biological effects of genetic polymorphisms

Polymorphism	Reference SNP No.	Biological effect	Reference
VEGFA -2578C/A	rs699947	Decreased VEGFA production	Koukourakis MI, et al. Lung Cancer. 2004;46:293-8
[F] 5'-CTGGAGCGTTTTGGTTAAATTGA-3'			
[R] 5'-AGTGGGACCAGTCAGTCTGATT-3'			
[S] 5'-GATTATCCACCCAGATC-3'			
VEGFA -1154G/A	rs1570360	Decreased VEGFA production	Shahbazi M, et al. J Am Soc Nephrol. 2002;13:260-4
[F] 5'-CTTGGTGGGGTTCGAGCT-3'			
[R] 5'-GGGACAGGCGAGCCTCAG-3'			
[S] 5'-CGAGCCCGTGTGGA-3'			
VEGFA -634G/C	rs2010963	Decreased VEGFA plasma levels	Watson CJ, et al. Cytokine. 2000;12:1232-5
[F] 5'-GGAAGAGAGAGACGGGGTCAGA-3'			
[R] 5'-GTCACCCCAAAAGCAGG-3'			
[S] 5'-GGCGTGCAGCAGC-3'			
VEGFA 936 C/T	rs3025039	Decreased VEGFA plasma levels	Renner W, et al. J Vasc Res. 2000;37:443-8
[F] 5'-AGACTCCGCGGAAGCATT-3'			
[R] 5'-TTCCGGGCTCGGTGATT-3'			
[S] 5'-CGGGCGGTGACCCA-3'			
MMP9 -1562C/T	rs3918242	Increased plasma MMP-9 level	Zhang B, et al. 1999;99:1788-94
[F] 5'-ATGCCGTAATCTAGCACTT-3'			
[R] 5'-TTTTGGGGGTGTAGTATCA-3'			
[S] 5'-CCCGAGTAGCTGGTATTATA-3'			
MMP9 836A/G	rs17576	Affects catalytic activity of MMP-9	Armstrong C, et al. Stroke. 2007;38:2895-9
[F] 5'-CACTTGGGGTTATAATGTGCT-3'			
[R] 5'-GGACCAATGAGAGTGAAAGACAA-3'			
[S] 5'-GCCCAGGACTCTACA-3'			
MMP9 2003G/A	rs17577	Increases bioavailability of active MMP-9	Cao J, et al. J Biol Chem. 1995;270:801-5
[F] 5'-ACACGCACGACGTCTTCCA-3'			
[R] 5'-TCCTCGCTCAGAATTTGACCA-3'			
[S] 5'-CACGACGTCTTCCAGTA-3'			
NOS3 -786T/C	rs2070744	Reduced promoter activity	Augeri AL, et al. Atherosclerosis. 2009;204:e28-34
[F] 5'-TTTCTCCAGCCCCTCAGATG-3'			
[R] 5'-CCCCACCTGTCAATTCA-3'			
[S] 5'-GGGCATCAAGCTCTTC-3'			
NOS3 894G/T	rs1799983	Reduced activation of NOS3	Tesauro M, et al. Proc Natl Acad Sci U S A. 2000;97:2832-5
[F] 5'-ACTCCCCACAGCTCTGCATT-3'			
[R] 5'-GGGGCAGAAGGAAGAGTT-3'			
[S] 5'-CAGAAGGAAGAGTTCTG-3'			
GSTP1 Ile105Val	rs1695	Decreased enzymatic activity, protracted oxaliplatin detoxification	Harries LW, et al. Carcinogenesis. 1997;18:641-4
[F] 5'-AGGACCTCCGCTGCAAATA-3'			
[R] 5'-CCTGGTGCAGATGCTCACATA-3'			
[S] 5'-CTCCGCTGCAAATAC-3'			

SNP, single nucleotide polymorphism; VEGFA, vascular endothelial growth factor A; F, forward; R, reverse; S, sequence; MMP, matrix metalloproteinase; NOS, nitric oxide synthase; GST, glutathione S-transferase.